Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05070520
Other study ID # 033/2020/CNERS
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 1, 2020
Est. completion date October 28, 2020

Study information

Verified date October 2021
Source Programme National de Lutte contre le Paludisme, Niger
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In Niger, malaria is a major public health problem. It is the main cause of morbidity and mortality among children. The management of malaria cases is based on the principle of early diagnosis and rapid treatment with effective drugs. It is confronted with the appearance of strains resistant to antimalarial drugs, hence the need to monitor antimalarial drug sensitivity. The study was conducted in three regions representing epidemiological strata of the country: Agadez (Centre de santé Intégré of Dagamanet in the Health district of Agadez), Maradi (Centre de santé intégré of Guindaoua in Tessaoua) and Dosso (Centre de santé Intégré centre in Gaya). The protocol used is the WHO standardized protocol of 2009. Artemether/Lumefantrine (AL) was administered with a 28-day follow-up in children aged 3 months to 15 years. A Polymerase Chain Reaction (PCR) correction is planned to differentiate between treatment failure and re-infestation as well as a study of genes responsible for resistance on the main drugs used.


Description:

The study took place from September 1 to October 31, 2020 at the time of peak malaria transmission. It took place at three sentinel sites of the National Malaria Control Program (NMCP). These were in the regions of i) Agadez at the Centre de Santé Intégré (CSI) of Dagamanet in the Agadez district, ii) Dosso at the CSI centre in the health district (HD) of Gaya iii) Maradi at the CSI Guindaoua in the HD of Tessaoua. These sites were identified by the NMCP because of their high attendance rate and belong to 3 different malaria epidemiological strata. As the treatment failure rate of artemether lumefantrine (AL) in the regions is unknown, 5% was chosen. With a confidence level of 95% and a precision around the estimate of 5%, a minimum of 73 patients were included. The number of patients was increased by 20% to account for possible dropouts and withdrawals during the 28/42 day follow-up period, 88 patients were included in the study per site. The study drug is oral AL. It is one of the four antimalarial drugs selected by the Niger's NMCP for the management of malaria. The product consists of blister packs of 6 tablets, box of 30 of lot number K U142 with an expiration date of January 2022 and blister packs of 12 tablets, box of 30 of lot number K U456 with an expiration date of January 2022. The AL combination was administered at a dose of 4 mg artemether and 24 mg lumefantrine per kg for three days. The AL was provided by the NMCP. The different prescriptions were as follows: - 5 to 15 Kg: 1 tablet, twice a day for three days. - 15 to 25 Kg: 2 tablets, twice a day for three days. - 25 to 35 kg: 3 tablets, twice a day for three days. - Over 35 kg: 4 tablets, twice a day for three days. The first day's intake was done under direct observation and possible side effects were noted. Any patient who persistently vomited after taking the medication was excluded from the study and treated with artesunate. Patients were followed up regularly until Day 28 and received a clinical examination with thick drop control and axillary temperature taking at Day 0, Day 1, Day 2, Day 3, Day 7, Day 14, Day 21, and Day 28. Capillary blood on filtered paper (Wattman) was routinely collected from all patients on the day of inclusion ( Day 0) and during follow-up for molecular analysis. For follow-up, the density of asexual parasite forms was assessed on the basis of 8 000 leukocytes per microliter of blood. All slides were read by two microscopists to ensure control. At the end of the follow-up, the response to treatment was classified according to clinical and parasitological criteria


Recruitment information / eligibility

Status Completed
Enrollment 259
Est. completion date October 28, 2020
Est. primary completion date September 30, 2020
Accepts healthy volunteers No
Gender All
Age group 3 Months to 15 Years
Eligibility Inclusion Criteria: - Brachial circumference (BC) > 125 mm and P/T z-score > -2 Standard Deviation (SD) - Age between three months and fifteen years, - Monospecific Plasmodium falciparum infestation detected by microscopy; - Parasitemia between 1000 and 200000 asexual parasitic forms/µl ; - Axillary temperature =37.5° or history of fever in the past 24 hours ; - Ability to take oral medications; - Ability and willingness to adhere to the protocol for the duration of the study and to adhere to the visit schedule ; - Informed consent of the accompanying person (guardian or parent). Exclusion Criteria: - Inability to take oral medications - History of antimalarial treatment in the past two weeks, including sulfadoxine-pyrimethamine (SPAQ) for seasonal malaria chemoprevention (SMC) - Lack of consent for pregnancy testing - Presence of general danger signs in children under five years of age or signs of severe P. falciparum malaria as defined by World Health Organization (WHO); - Mixed infestation or monospecific infestation with another Plasmodium species, detected by microscopic examination; - Severe malnutrition defined by a BC <125 mm AND P/T z-score < -3 Standard Deviation (SD) - Moderate malnutrition defined by a BC <125 mm AND a -3 =P/T z-score < -2 SD - Febrile condition due to illnesses other than malaria (e.g., measles, acute lower respiratory tract infection, severe diarrheal illness with dehydration) or other known chronic or severe underlying illnesses (e.g., cardiac, renal, or liver disease, HIV/AIDS) ; - Regular use of medications that may interfere with antimalarial pharmacokinetics; - History of hypersensitivity or contraindication to any of the drugs tested or used as replacement therapy; - Lack of informed consent from the patient or accompanying person

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Artemether-lumefantrine
Efficacy of artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in three sentinel sites in Niger (Agadez, Gaya and Tessaoua) in 2020

Locations

Country Name City State
Niger Programme National de Lutte Contre Le Paludisme Niamey

Sponsors (1)

Lead Sponsor Collaborator
Programme National de Lutte contre le Paludisme, Niger

Country where clinical trial is conducted

Niger, 

References & Publications (1)

Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000 Apr;94 Suppl 1:S1-90. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients with asexual falciparum parasitaemia on Day 0. Parasitaemia always refers to falciparum species. Mixed infections detected by light microscopy was excluded. 4 weeks
Primary Number of patiants with presence of gametocytes on Day 0 4 weeks
Primary Percentage of patients with danger signs of malaria on Day 1 Depending on the classification, a patient will be considered as having experienced treatment failure if the danger signs are associated with the presence of parasites. 4 weeks
Primary Proportion of patients with 'adequate clinical and parasitological response' (ACPR) before PCR-corrected absence of parasitaemia on day 28 (day 42), irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure 8 weeks
Primary Proportion of patients with 'adequate clinical and parasitological response' (ACPR) after PCR-corrected PCR analysis 24 weeks
Primary Proportion of patients with 'early treatment failure' (ETF) before PCR-corrected Danger signs or severe malaria on day 1, 2 or 3, in the presence of parasitaemia;
Parasitaemia on day 2 higher than on day 0, irrespective of axillary temperature;
Parasitaemia on day 3 with axillary temperature = 37.5 °C; and
Parasitaemia on day 3 = 25% of count on day 0
8 weeks
Primary Proportion of patients with 'early treatment failure' (ETF) after PCR-corrected -PCR analysis 24 weeks
Primary Proportion of patients with 'late clinical failure' (LCF) before PCR-corrected danger signs or severe malaria in the presence of parasitaemia on any day between day 4 and day 28 (day 42) in patients who did not previously meet any of the criteria of early treatment failure; and
presence of parasitaemia on any day between day 4 and day 28 (day 42) with axillary temperature = 37.5 °C in patients who did not previously meet any of the criteria of early treatment failure
8 weeks
Primary Proportion of patients with 'late clinical failure' (LCF) after PCR-corrected PCR analysis 24 weeks
Primary Proportion of patients with 'late parasitological failure' (LPF) before PCR-corrected presence of parasitaemia on any day between day 7 and day 28 (day 42) with axillary temperature < 37.5 °C in patients who did not previously meet any of the criteria of early treatment failure or late clinical failure. 8 weeks
Primary Proportion of patients with 'late parasitological failure' (LPF) after PCR-corrected PCR analysis 24 weeks
Primary Percentage of the known mutations associated with artemisinin resistance observed. PCR analysis 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Completed NCT02536222 - Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts Phase 4